Authors

Latest:

Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue Sarcomas

Neoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.

Dustin A. Deming, MD

Latest:

Precision Medicine Modeling Helps Advance Colorectal Cancer Care

Preclinical mouse models and cell lines link colorectal cancer subtypes subtypes with potential therapies.

Dustin Deming, MD, University of Wisconsin

Dustin M. Walters, MD

Latest:

Dr. Walters on the Best Approach to Treating Patients With Stage III Lung Cancer

Dustin M. Walters, MD, assistant professor, Thoracic and Cardiovascular Surgery, University of Virginia Health System, discusses the best approach to treating patients with stage III lung cancer.

Dwight L. Fitch, MD

Latest:

Dr. Fitch Discusses Dose Escalation of Radiation in Prostate Cancer

Dwight L. Fitch, MD, Radiation Oncologist, 21st Century Oncology in Bradenton, Florida, discusses dose modifications for radiation therapy in patients with prostate cancer.

Dylann Cohn-Emery

Latest:

Trispecific Antibody JNJ-79635322 Is Safe and Demonstrates Early Efficacy Signals in R/R Myeloma

JNJ-79635322 had a tolerable safety profile and elicited responses comparable with those generated by CAR T-cell therapy in relapsed/refractory myeloma.

E. David Crawford, MD

Latest:

Dr. Crawford on Ongoing Trials of Genetic Testing for Prostate Cancer

E. David Crawford, MD, professor of Radiation Oncology, University of Colorado School of Medicine, discusses ongoing trials regarding genetic testing for patients with prostate cancer.

E. David Crawford, MD, & Kyle O. Rove, MD

Latest:

Advanced Prostate Cancer: Therapeutic Sequencing, Outcomes, and Cost Implications

There is a dramatic revolution under way in the treatment of advanced-stage prostate cancer, which for many years consisted of systemic chemotherapy that offered only palliation of symptoms and no hope of improved survival.

E. David Crawford, MD, Neal D. Shore, MD

Latest:

Beyond PSA: A Summary Review of Predictive/Prognostic Biomarkers in Prostate Cancer

Although prostate cancer (PC) is the most common solid tumor malignancy among men in the Western Hemisphere, disease-specific mortality remains low, primarily due to optimized screening, diagnosis, and treatment.

E. David Crawford, MD, University of Colorado

E. David Crawford, MD, University of Colorado in Denver

E. Gabriela Chiorean, MD, FASCO

E. Gabriela Chiorean, MD, FASCO, is the clinical director of the GI Medical Oncology Program, professor in the Clinical Research Division, and affiliate investigator in the Translational Science and Therapeutics Division at Fred Hutchinson Cancer Center. She is also a professor of medicine at the University of Washington and director of the Clinical Research GI Oncology Program at the University of Washington/Fred Hutch.

Latest:

Dr Chiorean on Encorafenib Plus Cetuximab for BRAF V600E–Mutated mCRC

E. Gabriela Chiorean, MD, FASCO, discusses the FDA approval of encorafenib plus cetuximab and chemotherapy for patients with BRAF V600E–mutated mCRC.

E. Roy Berger, MD

Latest:

What to Look for in this Issue

The landscape for managing prostate cancer is changing rapidly. In recent months, we have seen two new drugs approved for hormone refractory advanced disease

E. Roy Berger, MD, FACP

Latest:

A Riddle, Wrapped in a Mystery, Inside an Enigma

At last year's American Society of Clinical Oncology (ASCO) meeting, the official focus was on seeing personalized cancer medicine translated from a theoretical approach to a practical one. As you will see in this issue of Oncology & Biotech News, success is being realized on this front.

Earle Burgess, MD

Latest:

Dr. Burgess on the Integration of PARP Inhibitors in Prostate Cancer

Earle Burgess, MD, discusses the integration of PARP inhibitors in advanced prostate cancer.

Ed Rabinowitz

Latest:

Rx for Protection Rather Than For Cure

Physicians tend to agree that the practice of defensive medicine is widespread, especially in oncology where much more is at stake than in the general practitioner's office. However, things can go drastically wrong.

Edgardo S. Santos, MD

Latest:

Dr. Santos on the Current Treatment Landscape in Squamous Cell Carcinoma of the Lung

Edgardo S. Santos, MD, FACP, discusses the current treatment landscape for patients with squamous cell carcinoma of the lung.

Edgardo S. Santos Castillero, MD, FACP, FASCO

Latest:

Amivantamab Toxicity Mitigation Strategies in the Treatment of EGFR-Mutant NSCLC

Panelists discuss how various strategies have been developed to enhance the tolerability of intravenous amivantamab, including premedication, step-up dosing, and infusion rate adjustments. Adoption into clinical practice varies, with many institutions integrating these approaches to mitigate infusion-related reactions and improve patient outcomes.

Edibaldo Silva, MD, PhD

Latest:

Back to the Future: Why Are More Women Having Bilateral Mastectomy for Unilateral Breast Cancer?

Since 2003, the rate of women choosing breast-conserving surgery for the management of early-stage breast cancer has declined, with an accompanying recidivism to mastectomy. Edibaldo Silva, MD, PhD, examines the reasons for the treatment regression.

Edith A. Perez, MD,

Latest:

Dr. Edith Perez on BOLERO-1 Results in HER2-Positive Breast Cancer

Edith Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, compares the results of the BOLERO-1 and BOLERO-3 trials.